Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$81,757.00-1.80%ETH$2,473.27-3.71%GOLD$4,160.60+0.09%OIL$90.99-0.55%
Smart Investors Daily
SID Premium
NR

NASDAQ · NRXS

NeurAxis, Inc.

Healthcare · Biotechnology

$6.83

Down-$0.06 (-0.88%)

Updated Oct 8, 2026, 8:23 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.12M
P/E ratio
-3.46
Dividend yield
0.00%
52-week range
$2.21 – $9.33
Volume
66.06K
Avg. volume
388.77K

Price performance · NRXS

NRXS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

NRXS closed at $6.83 after 21 trading sessions, up 19.20% for the selected period.

Last close
$6.83
Period change
+19.20%
Period low
$5.69
Period high
$7.76
Daily close
View OHLC price history
NRXS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$6.72$7.035$6.60$6.8366.06K
Oct 6, 2026$7.20$7.31$6.76$6.7866.54K
Oct 5, 2026$7.15$7.40$7.065$7.1553.78K
Oct 2, 2026$7.26$7.49$7.01$7.1147.41K
Oct 1, 2026$7.39$7.9499$7.00$7.17134.88K
Sep 30, 2026$7.81$7.98$7.28$7.3781.9K
Sep 29, 2026$7.53$8.05$7.50$7.76103.06K
Sep 28, 2026$7.56$7.68$7.28$7.4063.86K
Sep 25, 2026$7.69$7.99$7.56$7.56144.39K
Sep 24, 2026$7.30$7.75$7.15$7.75117.38K
Sep 23, 2026$7.32$7.53$6.94$7.3158.04K
Sep 22, 2026$7.20$7.56$7.13$7.31149.63K
Sep 21, 2026$7.69$7.69$7.11$7.14111.05K
Sep 18, 2026$7.67$7.81$7.37$7.61174.63K
Sep 17, 2026$7.34$8.06$7.25$7.63516.82K
Sep 16, 2026$6.14$7.74$6.14$6.941.08M
Sep 15, 2026$5.74$5.87$5.6101$5.7077.31K
Sep 14, 2026$5.69$6.00$5.31$5.75179.9K
Sep 11, 2026$5.77$5.77$5.645$5.7446.31K
Sep 10, 2026$5.70$5.7252$5.57$5.6950.25K
Sep 9, 2026$5.91$5.91$5.70$5.7336.35K

Latest NRXS news

The latest Smart Investors Daily articles mentioning NRXS.

Stock researchCompany · Overview

NRXS research

Overview

Company profile and research snapshot.

Company profile

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
8
NRXS recent ratings
DateFirmRatingTarget
Mar 20, 2026Craig-HallumBuy—
Dec 22, 2025Craig-HallumBuy—
Jun 16, 2025Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer

Yahoo · Sep 16, 2026

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The c

Yahoo · Sep 16, 2026

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By